E
Egbert F. Smit
Researcher at VU University Medical Center
Publications - 467
Citations - 30658
Egbert F. Smit is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 78, co-authored 413 publications receiving 26377 citations. Previous affiliations of Egbert F. Smit include Heidelberg University & VU University Amsterdam.
Papers
More filters
Journal ArticleDOI
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
TL;DR: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Journal ArticleDOI
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang,Suresh Senan,Marinus A. Paul,Reza J. Mehran,Alexander V. Louie,Peter A Balter,Harry J.M. Groen,Stephen E. McRae,Joachim Widder,Lei Feng,Ben E. E. M. van den Borne,Mark F. Munsell,Coen W. Hurkmans,Donald A. Berry,Erik van Werkhoven,John J. Kresl,Anne-Marie C. Dingemans,Omar Dawood,Cornelis J.A. Haasbeek,Larry S. Carpenter,Katrien De Jaeger,Ritsuko Komaki,Ben J. Slotman,Egbert F. Smit,Jack A. Roth +24 more
TL;DR: Overall survival for SABR versus surgery by pooling data from the STARS and ROSEL trials was 95% (95% CI 85-100) in the S ABR group compared with 79% in the surgery group, and recurrence-free survival at 3 years was 86% ( 95% CI 74-100).
Journal ArticleDOI
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares,M. Dvorkin,Y. Chen,Niels Reinmuth,Katsuyuki Hotta,D. Trukhin,Galina Statsenko,Maximilian Hochmair,Mustafa Ozguroglu,J.H. Ji,Oleksandr Voitko,A. Poltoratskiy,Santiago Ponce,Francesco Verderame,Libor Havel,Igor Bondarenko,Andrzej Kazarnowicz,György Losonczy,Nikolay Conev,Jon Armstrong,N. Byrne,Norah J. Shire,Haiyi Jiang,Jonathan W. Goldman,Emilio Batagelj,Ignacio Casarini,Anea Viviana Pastor,Susana Noemi Sena,J. J. Zarba,Otto C. Burghuber,Sylvia Hartl,Bernd Lamprecht,Michael Studnicka,Luis Alberto Schlittler,Fabricio Augusto Martinelli de Oliveira,Aknar Calabrich,Gustavo Girotto,Peo Dos Reis,Carlos Fausto Nino Gorini,Peo Rafael Martins De Marchi,Clarissa Serodio da Rocha Baldotto,Claudia Sette,Mauro Zukin,Assen Dudov,Rumyana Ilieva,Krassimir Koynov,Rositsa Krasteva,Ivan Tonev,Spartak Valev,Violetka Venkova,Minghong Bi,Chengshui Chen,Yuan Chen,Zhendong Chen,Jian Fang,Jifeng Feng,Zhigang Han,Jie Hu,Yi Hu,Wei Li,Zongan Liang,Zhong Lin,Rui Ma,Shenglin Ma,Kejun Nan,Yongqian Shu,Kai Wang,Mengzhao Wang,Gang Wu,Nong Yang,Zhixiong Yang,Helong Zhang,Wei Zhang,Jun Zhao,Yanqiu Zhao,Caicun Zhou,Jianying Zhou,Xiangdong Zhou,Vitezslav Kolek,Leona Koubkova,Jaromir Roubec,Jana Skrickova,Milada Zemanova,Christos Chouaid,Werner Hilgers,Hervé Lena,Denis Moro-Sibilot,Gilles Robinet,Pierre-Jean Souquet,Jürgen Alt,Helge Bischoff,Christian Grohe,E. Laack,Susanne Lang,Jens Panse,Christian Schulz,Krisztina Bogos,Eszter Csánky,Anea Fülöp,Zsolt Horváth,Judit Kósa,Ibolya Laczó,Gábor Pajkos,Zsuzsanna Papai,Zsolt Pápai Székely,Veronika Sárosi,Attila Somfay,Éva Somogyiné Ezer,Anás Telekes,Jair Bar,Maya Gottfried,Norman Isaac Heching,Alona Zer Kuch,Roberta Bartolucci,Anna Cecilia Bettini,Angelo Delmonte,Marina Chiara Garassino,Mauro Minelli,F. Roila,Shinji Atagi,Koichi Azuma,Hisatsugu Goto,Koichi Goto,Yu Hara,Hidetoshi Hayashi,Toyoaki Hida,Kenya Kanazawa,Shintaro Kanda,Young Hak Kim,Shoichi Kuyama,Tadashi Maeda,Masahiro Morise,Yasuharu Nakahara,Makoto Nishio,Naoyuki Nogami,Isamu Okamoto,Haruhiro Saito,Masahiro Shinoda,Shigeki Umemura,Tatsuya Yoshida,Niels Claessens,Robin Cornelissen,Lizza Heniks,Jeroen Hiltermann,Egbert F. Smit,Agnes Staal van den Brekel,Dariusz M. Kowalski,Slawomir Mandziuk,Robert Mróz,Marek Z. Wojtukiewicz,Tudor Ciuleanu,Doina Ganea,Anei Ungureanu,Alexander Luft,Vladimir Moiseenko,Dina Sakaeva,Alexey Smolin,Alexander Vasilyev,Lyubov Vladimirova,Igor Anasina,Jozef Chovanec,Pavol Demo,Robert Godal,Peter Kasan,Marian Stresko,Michal Urda,Eun Kyung Cho,Joo Hang Kim,Sang-We Kim,Gyeong-Won Lee,Jongmin Lee,Ki Hyeong Lee,Kyung Hee Lee,Yun Gyoo Lee,Maria Amelia Insa Molla,Manuel Domine Gomez,Juan Ignacio Delgado Mingorance,Dolores Isla Casado,Marta Lopez Brea,Margarita Majem Tarruella,Teresa Morán Bueno,Alejano Navarro Mendivil,Luis Paz-Ares Rodríguez,Santiago Ponce Aix,Maria Rosario Garcia Campelo,Gee-Chen Chang,Yen-Hsun Chen,Chao-Hua Chiu,Te Chun Hsia,Kang-Yun Lee,Chien-Te Li,Chin-Chou Wang,Yu-Feng Wei,Shang-Yin Wu,Ahmet Alacacioglu,Irfan Cicin,Ahmet Demirkazik,Mustafa Erman,Tuncay Göksel,Hryhoriy Adamchuk,Oleksii Kolesnik,Anna Kryzhanivska,Yuriv Ostapenko,Serhii Shevnia,Yaroslav Shparyk,Grygorii Ursol,Nataliia Voitko,Ihor Vynnychenko,Sunil Babu,Anne Chiang,Winston Chua,Shaker R. Dakhil,Afshin Dowlati,Basir Haque,Rodney Jamil,Jeanna Knoble,Shailena Lakhanpal,Kailhong Mi,Petros Nikolinakos,Steven Francis Powell,Helen Ross,Eric Schaefer,Jeffrey Schneider,Joseph Spahr,David R. Spigel,Joseph Stilwill,Christopher Sumey,M. Williamson +227 more
TL;DR: First-line durvalumab plus platinum-etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group and safety findings were consistent with the known safety profiles of all drugs received.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard,Egbert F. Smit,Harry J.M. Groen,Julien Mazieres,Benjamin Besse,Åslaug Helland,Vanessa Giannone,Anthony D'Amelio,Pingkuan Zhang,Bijoyesh Mookerjee,Bruce E. Johnson +10 more
TL;DR: Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC.
Journal ArticleDOI
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss,Martin L. Sos,Danila Seidel,Martin Peifer,Thomas Zander,Johannes M. Heuckmann,Roland T. Ullrich,Roopika Menon,Sebastian Maier,Alex Soltermann,Holger Moch,Patrick Wagener,Florian Fischer,Stefanie Heynck,Mirjam Koker,Jakob Schöttle,Frauke Leenders,Franziska Gabler,Ines Dabow,Silvia Querings,Lukas C. Heukamp,Hyatt Balke-Want,Sascha Ansén,Daniel Rauh,Ingelore Baessmann,Janine Altmüller,Zoe Wainer,Matthew Conron,Gavin M. Wright,Prudence A. Russell,Ben Solomon,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Steinar Sollberg,Odd Terje Brustugun,Walburga Engel-Riedel,Corinna Ludwig,Iver Petersen,Jörg Sänger,Joachim H. Clement,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egbert F. Smit,Daniëlle A.M. Heideman,Federico Cappuzzo,C. Ligorio,Stefania Damiani,Michael Hallek,Rameen Beroukhim,William Pao,Bert Klebl,Matthias Baumann,Reinhard Buettner,Karen Ernestus,Erich Stoelben,Jürgen Wolf,Peter Nürnberg,Peter Nürnberg,Sven Perner,Roman K. Thomas +62 more
TL;DR: F focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.